In this Wednesday, Sept. 24, 2014 file photo, health workers load a suspected Ebola patient into the back of an ambulance in Freetown, Sierra Leone. (AP Photo/Michael Duff, File)
Johnson & Johnson’s Janssen Pharmaceutical subsidiary said it started the first human phase of a clinical trial on a potential vaccine for Ebola, which has killed 8,153 people in Liberia, Guinea, Sierra Leone, according to World Health Organization figures.
The trial is being led by the Oxford Vaccine Group. J&J has also added production capacity to the effort, saying that more than 400,000 regimens of the vaccine have been produced and will be available by April. If the formula works, plans are in place for production of two million does through the end of 2015.
Read more at http://www.philly.com/philly/blogs/phillypharma/JJs-Janssen-Pharmaceutical-starts-phase-one-of-its-Ebola-vaccine-clinical-trial.html#7QZsUOq07QLoEjmA.99
Read more at http://www.philly.com/philly/blogs/phillypharma/JJs-Janssen-Pharmaceutical-starts-phase-one-of-its-Ebola-vaccine-clinical-trial.html#7QZsUOq07QLoEjmA.99
Nenhum comentário:
Postar um comentário